BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21666701)

  • 1. Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.
    Yu SJ; Yoon JH; Lee JH; Myung SJ; Jang ES; Kwak MS; Cho EJ; Jang JJ; Kim YJ; Lee HS
    Acta Pharmacol Sin; 2011 Jul; 32(7):912-20. PubMed ID: 21666701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.
    Cho EJ; Yu SJ; Kim K; Cho H; Cho YY; Lee YB; Lee JH; Kim YJ; Youn H; Yoon JH
    J Bioenerg Biomembr; 2019 Apr; 51(2):121-129. PubMed ID: 30746618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
    Said HM; Hagemann C; Carta F; Katzer A; Polat B; Staab A; Scozzafava A; Anacker J; Vince GH; Flentje M; Supuran CT
    Bioorg Med Chem; 2013 Jul; 21(13):3949-57. PubMed ID: 23706268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.
    Yu SJ; Yoon JH; Yang JI; Cho EJ; Kwak MS; Jang ES; Lee JH; Kim YJ; Lee HS; Kim CY
    J Bioenerg Biomembr; 2012 Feb; 44(1):101-15. PubMed ID: 22350012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.
    Perut F; Carta F; Bonuccelli G; Grisendi G; Di Pompo G; Avnet S; Sbrana FV; Hosogi S; Dominici M; Kusuzaki K; Supuran CT; Baldini N
    Expert Opin Ther Targets; 2015; 19(12):1593-605. PubMed ID: 26357839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulfonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity.
    Suthar SK; Bansal S; Lohan S; Modak V; Chaudhary A; Tiwari A
    Eur J Med Chem; 2013 Aug; 66():372-9. PubMed ID: 23827177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma.
    Huang WJ; Jeng YM; Lai HS; Fong IU; Sheu FY; Lai PL; Yuan RH
    PLoS One; 2015; 10(3):e0119181. PubMed ID: 25738958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression Dynamics of CA IX Epitope in Cancer Cells under Intermittent Hypoxia Correlates with Extracellular pH Drop and Cell Killing by Ureido-Sulfonamide CA IX Inhibitors.
    Sufian MA; Zamanova S; Shabana AM; Kemp B; Mondal UK; Supuran CT; Ilies MA
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
    Puccetti L; Fasolis G; Cecchi A; Winum JY; Gamberi A; Montero JL; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 May; 15(9):2359-64. PubMed ID: 15837325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of carbonic anhydrase IX is associated with poor prognosis through regulation of the epithelial‑mesenchymal transition in hepatocellular carcinoma.
    Hyuga S; Wada H; Eguchi H; Otsuru T; Iwgami Y; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
    Int J Oncol; 2017 Oct; 51(4):1179-1190. PubMed ID: 28849188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII.
    Akocak S; Güzel-Akdemir Ö; Kishore Kumar Sanku R; Russom SS; Iorga BI; Supuran CT; Ilies MA
    Bioorg Chem; 2020 Oct; 103():104204. PubMed ID: 32891000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors.
    Dubois L; Douma K; Supuran CT; Chiu RK; van Zandvoort MA; Pastoreková S; Scozzafava A; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):367-73. PubMed ID: 17502120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma.
    Kurt BZ; Dag A; Doğan B; Durdagi S; Angeli A; Nocentini A; Supuran CT; Sonmez F
    Bioorg Chem; 2019 Jun; 87():838-850. PubMed ID: 31003041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
    Kim W; Yoon JH; Jeong JM; Cheon GJ; Lee TS; Yang JI; Park SC; Lee HS
    Mol Cancer Ther; 2007 Sep; 6(9):2554-62. PubMed ID: 17876052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
    Cecchi A; Hulikova A; Pastorek J; Pastoreková S; Scozzafava A; Winum JY; Montero JL; Supuran CT
    J Med Chem; 2005 Jul; 48(15):4834-41. PubMed ID: 16033263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia.
    Akurathi V; Dubois L; Lieuwes NG; Chitneni SK; Cleynhens BJ; Vullo D; Supuran CT; Verbruggen AM; Lambin P; Bormans GM
    Nucl Med Biol; 2010 Jul; 37(5):557-64. PubMed ID: 20610160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer.
    Eldehna WM; Nocentini A; Al-Rashood ST; Hassan GS; Alkahtani HM; Almehizia AA; Reda AM; Abdel-Aziz HA; Supuran CT
    Bioorg Chem; 2018 Dec; 81():425-432. PubMed ID: 30219719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides.
    Franchi M; Vullo D; Gallori E; Pastorek J; Russo A; Scozzafava A; Pastorekova S; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Aug; 18(4):333-8. PubMed ID: 14567548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
    Petreni A; Bonardi A; Lomelino C; Osman SM; ALOthman ZA; Eldehna WM; El-Haggar R; McKenna R; Nocentini A; Supuran CT
    Eur J Med Chem; 2020 Mar; 190():112112. PubMed ID: 32044580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.
    Cianchi F; Vinci MC; Supuran CT; Peruzzi B; De Giuli P; Fasolis G; Perigli G; Pastorekova S; Papucci L; Pini A; Masini E; Puccetti L
    J Pharmacol Exp Ther; 2010 Sep; 334(3):710-9. PubMed ID: 20519553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.